Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-04-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事2020年度述职报告（陈命家）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. for the year 2020. It covers the director's attendance at board and shareholder meetings, independent opinions on various company matters including audit firm reappointment, related party transactions, internal controls, and fundraising projects. It also discusses the director's role in protecting investor rights, participation in board committees, and ongoing training. The content is a comprehensive explanation of the independent director's duties and activities over the fiscal year, which aligns with a Management Report rather than a simple announcement or certification. The document length is 4285 characters, which is substantial but not extremely long, and it contains substantive content rather than just a notice or announcement. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to the independent director's report on board activities and governance roles.
2021-04-07 Chinese
国元证券关于公司使用闲置自有资金和闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Guoyuan Securities) regarding the use of idle self-owned funds and idle raised funds by Anhui Anke Bioengineering (Group) Co., Ltd. for cash management. It includes regulatory references, approval procedures, risk assessments, and independent opinions. The document is not a financial report itself but a formal verification and opinion related to the company's cash management activities and compliance with regulatory requirements. It does not contain financial statements or quarterly/yearly financial data. The length is 3216 characters, which is relatively short and the document is more of a regulatory compliance and verification report. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and verification document rather than a financial report or announcement of a report.
2021-04-07 Chinese
关于召集召开2020年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice for convening the 2020 Annual General Meeting (AGM) of Anhui Anke Biotechnology (Group) Co., Ltd. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and voting instructions. The document does not contain the actual annual report or financial statements but rather the announcement and logistical details for the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length is over 5,000 characters and contains substantive meeting details, confirming it is not merely a brief announcement or regulatory filing.
2021-04-07 Chinese
关于续聘公司2021年度审计机构的公告
Audit Report / Information Classification · 90% confidence The document is an announcement regarding the reappointment of the company's audit firm for the 2021 fiscal year. It details the qualifications, experience, and integrity of the audit firm, the audit fees, and the approval process by the board and independent directors. It does not contain actual financial statements or audit reports but rather informs shareholders and the public about the intention to continue with the same audit firm, pending shareholder approval. The document length is 3238 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of Audit Report / Information (AR), as it relates to audit matters but is not a full annual report or audit report itself. However, since it is primarily an announcement about the audit firm appointment and not the audit report itself, it is best classified as AR (Audit Report / Information). FY 2021
2021-04-07 Chinese
关于举行2020年度业绩网上说明会的通知
AGM Information Classification · 90% confidence The document is a notice about holding an online performance briefing for the 2020 annual results. It mentions that the 2020 annual report has already been disclosed on April 8, 2021, and this notice is to invite investors to a webcast meeting to explain the results in more detail. The document is short (696 characters) and serves as an announcement for an event related to the annual report, not the report itself. Therefore, it fits the category of AGM Information (AGM-R) since it is about an annual performance meeting, or possibly an Investor Presentation (IP). However, since it is specifically about an annual performance explanation meeting (业绩说明会), which is typically considered an AGM-related event or an earnings presentation, and given the options, the best fit is AGM Information (AGM-R).
2021-04-07 Chinese
关于2020年度日常关联交易确认和2021年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the confirmation of 2020 daily related party transactions and the forecast of 2021 daily related party transactions by Anhui Anke Biological Engineering (Group) Co., Ltd. It includes transaction amounts, related parties, pricing principles, independent directors' opinions, and verification opinions by a securities company. The document is regulatory in nature, focusing on compliance with stock exchange rules and company law, and does not contain financial statements or comprehensive financial performance data. It is not an annual report, interim report, earnings release, or any other financial report type. It is also not a simple announcement of a report publication but a substantive regulatory disclosure about related party transactions. Therefore, it fits best under Regulatory Filings (RNS).
2021-04-07 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.